MarketCap
Facebook
X
Telegram
NGM Biopharmaceuticals Betriebszyklus | NGM
Betriebszyklus Jährlich NGM Biopharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 18.4 | - | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 18.4 | 18.4 | 18.4 |
Betriebszyklus anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebszyklus | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M |  USA |
 |
bluebird bio
BLUE
|
180 | - | - | $ 546 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
257 | - | - | $ 13.6 B | USA |
 |
Marinus Pharmaceuticals
MRNS
|
59.8 | - | - | $ 29.6 M | USA |
 |
NeuBase Therapeutics
NBSE
|
-65.8 | - | -1.56 % | $ 12.3 M | USA |
 |
CASI Pharmaceuticals
CASI
|
189 | - | - | $ 35.4 M | USA |
 |
Sigilon Therapeutics
SGTX
|
31.4 | - | - | $ 728 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Revance Therapeutics
RVNC
|
30.4 | - | - | $ 309 M | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
492 | $ 4.86 | 1.04 % | $ 787 M | USA |
 |
Epizyme
EPZM
|
47.2 | - | - | $ 249 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
8.16 K | - | -6.81 % | $ 3.04 B | USA |
 |
Nabriva Therapeutics plc
NBRV
|
214 | - | - | $ 4.55 M |  Irlanda |
 |
9 Meters Biopharma
NMTR
|
111 | - | -42.97 % | $ 1.05 M | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Theratechnologies
THTX
|
456 | - | - | $ 83.9 M |  Canada |
 |
Titan Pharmaceuticals
TTNP
|
81.3 | - | -3.76 % | $ 3.47 M | USA |
 |
scPharmaceuticals
SCPH
|
447 | - | - | $ 218 M | USA |
 |
Athersys
ATHX
|
73 | - | 3.77 % | $ 22.4 M | USA |
 |
Liquidia Corporation
LQDA
|
36.8 | $ 55.17 | 7.32 % | $ 4.75 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
361 | $ 317.17 | 0.96 % | $ 6.13 B | USA |
 |
Global Blood Therapeutics
GBT
|
5.46 K | - | - | $ 4.62 B | USA |
 |
MannKind Corporation
MNKD
|
457 | $ 4.18 | -1.3 % | $ 1.28 B | USA |
 |
Merck & Co.
MRK
|
204 | $ 147.17 | -0.57 % | $ 368 B | USA |
 |
NanoString Technologies
NSTG
|
311 | - | -37.43 % | $ 5.1 M | USA |
 |
Humanigen
HGEN
|
598 | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
125 | - | -29.58 % | $ 126 M | USA |
 |
Surface Oncology
SURF
|
7.98 | - | - | $ 59.7 M | USA |
 |
Intellia Therapeutics
NTLA
|
23 | $ 11.46 | 2.6 % | $ 1.24 B | USA |
 |
Cocrystal Pharma
COCP
|
78.2 | $ 1.02 | -0.97 % | $ 11.5 M | USA |
 |
Mesoblast Limited
MESO
|
0.01 | $ 13.64 | -2.5 % | $ 16.5 B |  Australia |
 |
Vaccinex
VCNX
|
546 | - | -61.37 % | $ 654 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
17.9 | - | -19.68 % | $ 18.4 M | Canada |
 |
Pliant Therapeutics
PLRX
|
229 | $ 0.78 | -0.57 % | $ 47.9 M | USA |